[20020131]RS21129_药品专利期限延长:简要说明.pdf

上传人:任我行 文档编号:16049 上传时间:2022-06-24 发布时间:2002-05-06 格式:PDF 页数:5 大小:26.15KB
下载 相关 举报
[20020131]RS21129_药品专利期限延长:简要说明.pdf_第1页
第1页 / 共5页
[20020131]RS21129_药品专利期限延长:简要说明.pdf_第2页
第2页 / 共5页
[20020131]RS21129_药品专利期限延长:简要说明.pdf_第3页
第3页 / 共5页
[20020131]RS21129_药品专利期限延长:简要说明.pdf_第4页
第4页 / 共5页
[20020131]RS21129_药品专利期限延长:简要说明.pdf_第5页
第5页 / 共5页
亲,该文档总共5页,全部预览完了,如果喜欢就下载吧!
资源描述

1、Congressional Research Service The Library of CongressCRS Report for CongressReceived through the CRS WebOrder Code RS21129January 31, 2002Pharmaceutical Patent Term Extensions: ABrief ExplanationWendy H. SchachtSpecialist in Science and TechnologyResources, Science, and Industry DivisionJohn. R. Th

2、omasVisiting Scholar in Economic Growth and EntrepreneurshipResources, Science, and Industry DivisionSummaryThe pharmaceutical industry appears to place a high value on patents and drugcompanies frequently obtain patent protection and enforce patent rights. Patents permitthe owner to exclude others

3、from making, using, importing, or selling the patentedinvention. Patents are issued by the U.S. Patent and Trademark Office (USPTO),generally for a term of 20 years from the date of filing. However, certain circumstancespermit extensions to the term of the patent, including delays in the initial adm

4、inistrativeprocess at the USPTO. More significantly, the Drug Price Competition and Patent TermRestoration Act of 1984, commonly known as the “Hatch-Waxman” Act, permitslimited extensions to compensate for market time lost during the drug approval processundertaken by the Food and Drug Administratio

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告